Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Tallman, Martin S  [Clear All Filters]
2013
Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, Leduc CA, Kelly K, Jalas C, Paietta E, Racevskis J, Rowe JM, et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.
2015
Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. Hematol Oncol. 2015.
2016
Kumar AJ, Gimotty PA, Gelfand J, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, et al. Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol. 2016.
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, et al. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol. 2016;136(4):210-218.
2019
DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Knorr DA, Goldberg AD, Stein EM, Tallman MS. Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. Leuk Lymphoma. 2019:1-13.
2020
Stein EM, Fathi AT, Dinardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020.
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SOctavian, Holtzman NG, Ii GLPhillips, Devine SM, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Foss FM, Wang XVictoria, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, et al. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020.
Stahl M, Tallman MS. Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission. Br J Haematol. 2020.
2021
Bewersdorf JPhilipp, Allen C, Mirza A-S, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant - a systematic review and meta-analysis. Transplant Cell Ther. 2021.
Brambilla CZuanelli, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, et al. Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.
2022
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. 2022.